These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20396720)

  • 1. Effect of combination of anticytokine preparations anaferon and artrofoon on immune inflammation in rheumatoid arthritis.
    Petrov VI; Babaeva AR; Solodenkova KS; Cherevkova EV; Zabolotneva YA; Kachanova MV; Sergeeva SA
    Bull Exp Biol Med; 2009 Sep; 148(3):489-92. PubMed ID: 20396720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiated antibodies to tumor necrosis factor-alpha in the therapy of patients with rheumatoid arthritis.
    Kozlovskaya LV; Mukhin NA; Rameev VV; Sarkisova IA; Epstein OI
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():152-4. PubMed ID: 12949685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency of potentiated antibodies to tumor necrosis factor-alpha (Artrofoon) in the therapy of patients with rheumatoid arthritis.
    Petrov VI; Babaeva AR; Cherevkova EV; Epstein OI; Sergeeva SA
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():155-8. PubMed ID: 12949686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.
    Assous N; Gossec L; Dougados M; Kahan A; Allanore Y
    Clin Exp Rheumatol; 2007; 25(3):504. PubMed ID: 17631755
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficiency and safety of long-term artrofoon treatment in rheumatoid arthritis.
    Petrov VI; Babaeva AR; Cherevkova EV; Kachanova MV; Zabolotneva YA; Tarasov SA; Dugina YL; Sergeeva SA
    Bull Exp Biol Med; 2009 Sep; 148(3):486-8. PubMed ID: 20396719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms].
    Wollheim FA
    Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination DMARD therapy for rheumatoid arthritis.
    Kremer JM
    Manag Care; 2001 Jul; 10(7 Suppl):10-4. PubMed ID: 11729428
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticytokine therapy--a new era in the treatment of rheumatoid arthritis?
    O'Dell JR
    N Engl J Med; 1999 Jan; 340(4):310-2. PubMed ID: 9920958
    [No Abstract]   [Full Text] [Related]  

  • 11. [Infliximab for therapy of rheumatoid arthritis].
    Amano K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():517-20. PubMed ID: 15799410
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficiency and tolerability of artrofoon in patients with rheumatoid arthritis associated with osteopenic syndrome.
    Peshekhonova LK; Chernov YN; Barsukova NA; Peshekhonov DV
    Bull Exp Biol Med; 2009 Sep; 148(3):468-9. PubMed ID: 20396714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 16. Rheumatoid arthritis.
    Burchini G; Orsi C
    N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract]   [Full Text] [Related]  

  • 17. Experimental and clinical study of the effect of artrofoon on proinflammatory cytokine production.
    Kachanova MV; Sherstoboyev EY; Babayeva AR; Tcherevkova EV; Dugina JL; Kislitsyna OS; Epstein OI; Sergeeva SA
    Bull Exp Biol Med; 2008 Jan; 145(1):58-61. PubMed ID: 19024003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha.
    Richez C; Blanco P; Gin H; Schaeverbeke T
    Clin Exp Rheumatol; 2006; 24(5):607. PubMed ID: 17181936
    [No Abstract]   [Full Text] [Related]  

  • 19. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab for rheumatoid arthritis in a patient with tuberculosis.
    Matsumoto T; Tanaka T; Kawase I
    N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.